Creative Medical Technology Holdings Inc. (CELZ) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, CELZ scores 20 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars, the Fundamental Cash Engine scores 3/20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F Flow scores 5/20, reflecting institutional accumulation and options positioning that is weak relative to the scoring frame. Insider Conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 7/20 with a Beta of 1.0 and noted sector sensitivity. Forensic Balance Sheet scores 2/20, with an Altman Z of 0.2, a Piotroski F of 3/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the implications are that the rating framework identifies few upside drivers: cash generation, ownership flow, and balance-sheet strength all register at or near the bottom of their ranges. The price of 0.68 sits near the low end of the 52-week range of $0.62 - $4.72, and the market capitalization of $5.2M leaves limited valuation cushion against continued operating losses. Any valuation thesis would have to rest on future cash generation that the source data does not currently demonstrate. The forensic metrics are the most concerning element, since a 0.2 Altman Z combined with a 3/9 Piotroski F points to elevated financial distress risk per the RQD framework.

Per the SEC financials, reported operating and net losses persisted across FY 2023 through FY 2025 with no revenue recorded in any displayed period. Per the market data, the operating margin and net margin are each -60%, while the gross margin is 63.4%. ROIC is -35% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and the Debt/Equity ratio is 0.5. Cash and debt balances are not available in source data for any period.

The news wire contains six items, all tagged to CELZ and all carrying a YELLOW light. Three are general market-coverage pieces from StockInvest.us, Simply Wall St, and TradingView describing stock price forecasts and analyst-style commentary without substantive new fundamental detail. A Stock Titan item reports that average knee pain scores fell about 65% over six months in a 30-person study. A Quiver Quantitative item highlights positive Ultrasome™ pilot data in a knee osteoarthritis study. A Benzinga item lists CELZ among 12 Health Care stocks moving in a pre-market session. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded. The clinical pilot items are the only company-specific catalysts in the feed, and the source data does not include study scope, regulatory status, or commercial pathway detail.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology: Biological Products industry classification. An investor should watch whether any future clinical or regulatory developments create dependencies that the current graph does not capture, and whether the Health Care sector and biological products industry trends affect the stock through the Macro Regime Fit pillar's noted sector sensitivity.

• What is the company's cash and debt position in each reporting period, since both are listed as N/A in the SEC financials?
• What revenue source, if any, underlies the reported $0.0M revenue, and what is the commercial pathway for the Ultrasome™ program?
• What is the scope, size, and regulatory status of the knee osteoarthritis pilot study beyond the headline results?
• How does the company plan to fund continuing operating losses of roughly $6M per year given a $5.2M market capitalization and a 0.2 Altman Z?
• What institutional, insider, and analyst holdings exist, given that the holders and analyst data sections are empty?